Ductal carcinoma
Also known as: Ductal, Ducts
Methodology & AI Transparency ⓘ
Ductal carcinoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Cancer, Oncology & Supportive Care practice, Ductal carcinoma (also termed Ductal or Ducts) (ICD-10 C80.1) is stratified through tissue biopsy with in Ductal carcinoma (C80.1: histopathology), pairing targeted symptom control with longitudinal Complete Blood Count in Ductal carcinoma (C80.1: (ANC, Hemoglobin, Platelets)) surveillance.
- 2 Real-world patient consensus: Mapped to Cancer, Oncology & Supportive Care under ICD-10-CM C80.1 for Ductal carcinoma clinical workups.
- 3 Typical cash cost range: Primary evaluation for Ductal carcinoma incorporates tissue biopsy with in Ductal carcinoma (C80.1: histopathology) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Ductal carcinoma: maintaining Pathology / Molecular in Ductal carcinoma (C80.1: Genomic Staging) within Guideline-concordant surveillance (C80.1).
Ask our AI Specialists anything about Ductal carcinoma
What Is Ductal carcinoma?
Within Cancer, Oncology & Supportive Care practice, Ductal carcinoma (also termed Ductal or Ducts) (ICD-10 C80.1) is stratified through tissue biopsy with in Ductal carcinoma (C80.1: histopathology), pairing targeted symptom control with longitudinal Complete Blood Count in Ductal carcinoma (C80.1: (ANC, Hemoglobin, Platelets)) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Ductal carcinoma (code C80.1) is tumor-suppressor loss enabling in Ductal carcinoma (C80.1: clonal proliferation), which Cancer, Oncology & Supportive Care clinicians address while surveilling Pathology / Molecular in Ductal carcinoma (C80.1: Genomic Staging) (Guideline-concordant surveillance (C80.1)).
Common Symptoms & Clinical Signs
- • Presentation of Ductal carcinoma (C80.1): unintended weight loss [Ductal carcinoma C80.1]
- • Secondary Ductal carcinoma clinical sign: unexplained bleeding, chronic in Ductal carcinoma (C80.1: hoarseness/cough, or progressive)
- • Symptom flares in Ductal carcinoma correlating with Pathology / Molecular in Ductal carcinoma (C80.1: Genomic Staging) deviation outside Guideline-concordant surveillance (C80.1)
- • Functional cancer & oncology impact requiring tissue biopsy with in Ductal carcinoma (C80.1: histopathology) evaluation (C80.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Ductal carcinoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C80.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Ductal carcinoma (C80.1: Genomic Staging) | Guideline-concordant surveillance (C80.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Ductal carcinoma (C80.1: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C80.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Ductal carcinoma (C80.1: Organ Function Panel) | Preserved renal/hepatic clearance (C80.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Ductal carcinoma
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Hexaminolevulinate Hydrochloride Cysview • RxCUI RXN-105113001-1757 | FDA Prescription Therapeutic Agent | 88% | $1.0700 | $ 51.84 /mo |
| Sorafenib Nexavar • RxCUI 597747 | Kinase Inhibitor | 94% | $1.2800 | $ 60.34 /mo |
| Goserelin Zoladex • RxCUI 105641 | Gonadotropin Releasing Hormone Receptor Agonist | 78% | $2.5500 | $ 111.78 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ductal carcinoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Ipatasertib plus abiraterone had an overall tolerable safety profile consistent with known toxicities. Clinical genitourinary cancer • 2023-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36697317 ↗ |
| New Insights on Long-term Survival Outcomes of 'Low Risk' Ductal Carcinoma in situ from a: What a 372-Participant Study Found Long-term survival of DCIS was excellent, especially in low risk DCIS, regardless of surgical treatment. Clinical oncology (Royal College of Radiologists (Great Britain)) • 2021-01-15 • Phase III Randomized Trial | N = 372 | 87/100 | PMID 32713775 ↗ |
| New Insights on Phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and: What a 546-Participant Study Found In patients with curatively D2-resected, stage II/III, node-positive GC, adjuvant SOX or SOXRT was effective in prolonging DFS, when compared with S-1 single-drug treatment. Annals of oncology : official journal of the European Society for Medical Oncology • 2021-03-15 • Phase III Randomized Trial | N = 546 | 87/100 | PMID 33278599 ↗ |
| New Insights on Prognostic Subgroups for Disease-Free Survival With Cutaneous Squamous Cell: What a 321-Participant Study Found Of 321 patients randomized, 310 (23 female individuals [7%] and 287 male individuals [93%]; median [range] age, 64 [32-85] years) initiated the allocated treatment. JAMA otolaryngology-- head & neck surgery • 2025-10-01 • Phase III Randomized Trial | N = 321 | 87/100 | PMID 40875250 ↗ |
| New Insights on Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib: What a 636-Participant Study Found This reconstructed-data post hoc analysis suggested exploratory time-dependent patterns in effect estimates without formal evidence of a time-varying. International journal of urology : official journal of the Japanese Urological Association • 2026-07-15 • Phase III Randomized Trial | N = 636 | 87/100 | PMID 42502892 ↗ |
Ductal carcinoma Patient Community & “People Like Me” Threads
Filter Ductal carcinoma community threads and patient logs by age, biological sex, dosage, and treatment duration.